Physician profile
Deepak Tikku
NPI 1689748345
$2,527.46
in general payments reported to CMS, 2019-2025
24 companies · $906 in 2025
The $906 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $405 · 2020: $265 · 2021: $101 · 2022: $185 · 2023: $151 · 2024: $515 · 2025: $906.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,522 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,522.32 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $853.73 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $269.45 | 2019-2020 | |
| Genzyme Corporation | $229.94 | 2020-2023 | |
| Teva Pharmaceuticals USA, INC. | $137.31 | 2020-2025 | Austedo Xr, Austedo |
| Alexion Pharmaceuticals, INC. | $107.11 | 2019-2024 | Ultomiris |
| Otsuka America Pharmaceutical, INC. | $101.36 | 2024-2025 | Rexulti |
| Lilly USA, LLC | $95.24 | 2019-2024 | Amyvid |
| Sk Life Science, INC. | $89.94 | 2020-2025 | |
| Amgen INC. | $88.11 | 2022-2025 | Uplizna, Aimovig |
| Argenx US, INC. | $61.74 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Supernus Pharmaceuticals, INC. | $60.20 | 2019-2020 | |
| Lundbeck LLC | $47.29 | 2022-2024 | Vyepti |
| Janssen Biotech, INC. | $43.23 | 2025 | |
| Genentech USA, INC. | $41.66 | 2019 | |
| Allergan, INC. | $41.46 | 2020-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $40.55 | 2019 | |
| Emd Serono, INC. | $36.39 | 2019 | |
| Eisai INC. | $34.19 | 2023-2024 | |
| Pfizer INC. | $32.51 | 2024-2025 | |
| Acorda Therapeutics, INC | $31.52 | 2023-2024 | Ampyra, Inbrija |
| Aucta Pharmaceuticals, INC. | $27.95 | 2025 | Motpoly Xr |
| Neurocrine Biosciences, INC. | $23.34 | 2025 | |
| Janssen Pharmaceuticals, INC | $16.91 | 2023 | |
| Amneal Pharmaceuticals LLC | $16.33 | 2025 | Crexont |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepak Tikku listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.